TY - JOUR
T1 - Microbiome Therapeutics for Clostridioides difficile Infection
AU - Lucky, Christine W.
AU - Medernach, Rachel L.
AU - Kelly, Brendan J.
AU - Kwon, Jennie H.
AU - Woodworth, Michael H.
N1 - Publisher Copyright:
© 2025 Elsevier Inc.
PY - 2025/12
Y1 - 2025/12
N2 - Microbiota-based therapies are used increasingly for the treatment and prevention of Clostridioides difficile infection (CDI), particularly in cases of recurrent CDI (rCDI). This review discusses the different types of microbiota-based therapies, including fecal microbiota transplant, fecal microbiota products, and live biotherapeutic products. The authors present efficacy data regarding clinical use in rCDI and highlight the unique aspects of each product.
AB - Microbiota-based therapies are used increasingly for the treatment and prevention of Clostridioides difficile infection (CDI), particularly in cases of recurrent CDI (rCDI). This review discusses the different types of microbiota-based therapies, including fecal microbiota transplant, fecal microbiota products, and live biotherapeutic products. The authors present efficacy data regarding clinical use in rCDI and highlight the unique aspects of each product.
KW - Clostridioides difficile infection
KW - Fecal microbiota products
KW - Fecal microbiota transplant
KW - Live biotherapeutic products
KW - Microbiome
KW - Recurrent C difficile
UR - https://www.scopus.com/pages/publications/105013132950
U2 - 10.1016/j.idc.2025.07.007
DO - 10.1016/j.idc.2025.07.007
M3 - Article
C2 - 40796472
AN - SCOPUS:105013132950
SN - 0891-5520
VL - 39
SP - 663
EP - 683
JO - Infectious disease clinics of North America
JF - Infectious disease clinics of North America
IS - 4
ER -